Mosanna Therapeutics reports positive phase 1 MOSAIC results for MOS118

The company said MOS118 was safe and well tolerated across dose cohorts in healthy volunteers. It plans to evaluate nightly dosing over seven days in 24 patients with obstructive sleep apnea.